No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CR Crane
- 141.000
- -3.270-2.27%
Trading Apr 30 13:55 ET
8.05BMarket Cap37.44P/E (TTM)
145.290High140.140Low77.34KVolume144.490Open144.270Pre Close11.03MTurnover0.16%Turnover Ratio42.61P/E (Static)57.09MShares146.28552wk High8.35P/B6.87BFloat Cap70.77552wk Low0.75Dividend TTM48.74MShs Float146.285Historical High0.53%Div YieldTTM3.57%Amplitude66.757Historical Low142.568Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
CICB Senior Crane Instructor and Inspector, Jeffrey Palacios, Appointed to the CCO Spanish Bilingual Committee
Jeffrey Palacios was recently appointed to the CCO Spanish Bilingual Committee. Palacios, a certified crane instructor, brings his years of...
United States Industrial Valve Market Insights Report 2024-2029 Featuring Key Vendors - Bray International, Crane, Emerson Electric, Flowserve, SLB, Baker Hughes, Danfoss, KITZ, SMC, and Velan - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "U.S. Industrial Valve Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.The U.S. industrial valve market is expected to reac
CR Double-Crane Pharmaceutical's Profit Rises 11% in Q1 as Revenue Grows 2%
China Resources Double-Crane Pharmaceutical (SHA:600062) posted an 11% year-over-year increase in attributable net profit in the first quarter of 2024 to 416.1 million yuan from 374.9 million yuan, th
CR Double-Crane Pharmaceutical's Unit Gets Nod to Trial New Pain Medication
China Resources Double-Crane Pharmaceutical's (SHA:600062) unit, China Resources Shuanghe Limin Pharmaceutical (Jinan), will conduct clinical trials on pregabalin extended-release tablets after receiv
Calculating The Intrinsic Value Of Crane NXT, Co. (NYSE:CXT)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Crane NXT fair value estimate is US$70.42 With US$62.87 share price, Crane NXT appears to be trading close to its estimated fair value Our
Crane Raised to Buy From Hold by Vertical Research
Crane Raised to Buy From Hold by Vertical Research
Comments
Insiders selling shares below current price and lack of purchases over the past year raises caution. Despite ownership, their selling activity suggests a lack of urgency to buy. However, company's earnings growth is positive.
Possible Bearish Signals With Crane Insiders Disposing Stock 2
Insiders selling shares below current price could indicate they believe shares are fully valued. Modest insider ownership suggests some alignment with other shareholders.
1
The growth in profits and high level of insider ownership in Crane makes it an appealing stock to keep an eye on. The alignment of goals between shareholders and management is seen as a positive sign.
Crane's dwindling capital base is worrisome. If this persists, the company may shrink, potentially hindering its multi-bagger status. Despite strong stock performance in the past five years, underlying trends must improve for sustained optimism.
Despite Crane's shrinking earnings, its P/E ratio remains steady. Share prices risk falling unless conditions improve. Investors hope for a business turnaround, but analysts are skeptical.
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg